Program
TNX-103
A development code.
Its studies are mostly in Heart Failure · Hypertension, Pulmonary, led by Tenax Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tenax Therapeutics | 33 open or running | phase 3since Aug 1, 2023 | Aug 1, 2023 | Jun 30, 2028phase 3 · NCT07288398 |
Also a collaborator on its studies: medpace-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 1, 2023First study: phase 3 study in Hypertension, PulmonaryFirst studyNCT05983250 · 230 enrolled · United States, Canada
- Dec 15, 2025Phase 3 study in Heart FailureNCT07288398 · 540 enrolled · United States, Argentina, Austria and more
- Feb 20, 2026Phase 3 study in Heart FailureNCT07436689 · 800 planned · United States
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Heart FailureNCT07288398
- Mar 2029Primary completion: phase 3 study in Heart FailureNCT07436689
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07436689Heart Failure · United States | 3 | By invitation | Mar 2029 | 800 |
| NCT07288398Heart Failure · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jun 30, 2028 | 540 |
| NCT05983250Hypertension, Pulmonary · United States, Canada | 3 | Active, not recruiting | Jun 30, 2026 | 230 |
How it is read
Names in the registry
- “TNX-103”, 3 entries
Codes read as this program: TNX103.
Conditions, from the studies’ own filings
- Heart Failure, 2 studies
- Hypertension, Pulmonary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.